Basket Clinical Trials: A New Era in Cancer Treatment

TOP - August 2017, Vol 10, No 3 - Conference Correspondent, HOPA 2017 Highlights
Chase Doyle

Anaheim, CA—Precision medicine continues to transform oncology, and it is not just the treatments that are changing; decades-old drug clinical trial designs have been remodeled to accommodate an evolving understanding of genetic drivers in cancer.

Basket clinical trials, which test the effect of ≥1 drugs on ≥1 mutations in several cancer types, are an example of this innovative study design. Dazhi Liu, PharmD, BCOP, Developmental Therapeutic Clinic, Memorial Sloan Kettering Cancer Center, New York City, shared the success of recent basket studies at the 2017 Hematology/Oncology Pharmacy Association Annual Conference.

“Basket studies can accelerate biologic validation of new targets, including rare cancers, rare actionable alterations, and pediatric cancers,” said Dr Liu.

Historically, targeted therapy studies have been limited to 1 tumor type, said Dr Liu. If a patient tested positive for a mutation, he or she was randomized to a selective inhibitor or chemotherapy that is often ineffective. However, recent data confirm that genetic mutations are seldom limited to a single histology, although the implication for treatment remains unclear. He discussed an example of studies with crizotinib (Xalkori).

“We know that patients with ALK-positive non–small-cell lung cancer can benefit from crizotinib, but the ALK rearrangement is seen in other types of cancer, too,” said Dr Liu. “With this many cancers and genetic drivers, clinicians and drug developers need to study therapeutic agents based on genetic drivers, not histology,” he emphasized.

Vemurafenib Basket Study

In the past decade, umbrella studies, basket studies, and master/molecular allocation studies have been introduced to resolve these issues, said Dr Liu.

Vemurafenib (Zelboraf), an oral BRAF inhibitor with selectivity for the BRAF V600E mutation form of the kinase, is FDA approved for patients with unresectable or metastatic melanoma and the BRAF V600E mutation. In a recent basket study, however, vemurafenib was used in a variety of cancers with different primary disease sites and histologies, including lung cancer, cholangiocarcinoma, Erdheim-Chester disease and Langerhans-cell histiocytosis, anaplastic thyroid cancer, ovarian cancer, multiple myeloma, and colorectal cancer.

“The basket study yielded exciting discoveries,” said Dr Liu. “In the cohort of Erdheim-Chester disease and Langerhans-cell histiocytosis, for example, all patients enrolled in the study demonstrated fast and durable disease regression. In the past, these were considered orphan diseases without any treatment,” he said.

In another cohort, a singer who had not responded to multiple lines of previous therapy for glioblastoma had nearly a complete response to vemurafenib and was able to return to the stage after treatment.

“These results inspire us as investigators to bring this basket trial to our patients,” said Dr Liu. “Regardless of diagnosis, we’re seeing that it’s never a hopeless situation.”

“When the study moves to the next phase of development, we then have a better chance of keeping patients on the study so that their disease may benefit from the treatment,” explained Dr Liu.

Related Items
ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals
Chase Doyle
TOP Web Exclusives published on April 9, 2018 in Leukemia
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern
Chase Doyle
TOP Web Exclusives published on April 9, 2018 in Immunotherapy
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, AONN+ News
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Combining Immunotherapy and Radiotherapy Shows Good Synergy
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Immunotherapy, Conference Correspondent
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News
Last modified: August 2, 2017